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AbstrAct:
Colorectal cancer metastatic recurrence and chemoresistance are major causes 
of morbidity and mortality. Colon cancer initiating cells (CCIC) are thought to 
contribute to both these processes. To identify drugs with anti-CCIC activity we 
screened a number of FDA approved and investigational compounds. We found 
that the class I selective histone deacetylase inhibitor (HDACi) MGCD0103 has 
significant activity against CCIC, and also significantly inhibits non-CCIC CRC cell 
xenograft formation. Both MGCD0103 and the pan-HDAC inhibitor Trichostatin 
impairs CCIC clonogenicity and cause cell cycle arrest and cell death. Gene 
expression  profiling  revealed  that  the  canonical  WNT  ligand  DKK-1 is a highly 
upregulated target of HDAC inhibitors. Despite the presence of APC mutations 
and constitutive WNT signaling in CCIC, both transfected and recombinant DKK-1 
dramatically inhibit CCIC proliferation and clonogenicity. Overall, these data show 
that inhibition of class I HDACs is a promising novel approach to target both CCIC 
and non-CCIC CRC cells. Our studies also provide novel insights into roles for DKK1 
in addition to canonical WNT signaling and the mechanism of CCIC tumor formation.
IntroductIon 
Colorectal cancer (CRC) is the 2nd leading cause of 
cancer death in the United States. Chemotherapy is the 
primary form of treatment once CRC has spread beyond the 
colon. However, in most cases tumors recur and become 
refractory to chemotherapy. In part, tumor recurrence and 
chemoresistance is attributed to stochastic genetic and 
epigenetic changes, which cause selection of resistant 
clones that form new tumors. Recently, an additional 
mechanism of tumor recurrence and chemoresistance has 
been proposed. This mechanism postulates that a minority 
of cells in a tumor (referred to as cancer stem cells or 
cancer initiating cells) are intrinsically more chemo- and 
radiation resistant [1, 2]. In support of this model, recent 
studies have demonstrated that these cells express high 
levels of DNA damage response genes, which contribute 
to chemoresistance [3]. They also have lower reactive 
oxygen species (ROS) levels as another mechanism 
conferring resistance to radiation, and in fact have less 
DNA damage after ionizing radiation [4]. These cells also 
express high levels of drug efflux transporter genes that 
also lead to chemoresistance and relapse [5]. 
Recent CRC focused studies show that colon 
cancer initiating cells (CCIC) are enriched in xenogenic 
tumors growing in mice treated with chemotherapy, and 
that CCIC rapidly regenerate new tumors even with 
concurrent therapy [6, 7]. Additionally, high NOTCH 
signaling levels cause CRC chemoresistance [8] and our 
own recent studies show that CCIC have 10-30X higher 
NOTCH levels than non-CCIC CRC cells as a potential 
mechanism of chemoresistance and tumor recurrence [9]. Oncotarget 2010; 1:  596 - 605 597 www.impactjournals.com/oncotarget
As CCIC are thought to both self-renew and give 
rise to non-CCIC CRC cancer cells that populate tumors, 
epigenetic control of gene expression has been proposed 
as a likely mechanism to regulate the CCIC to non-CCIC 
CRC cancer cell transition. Drugs that modulate epigenetic 
state are therefore a promising approach for anti-CCIC 
targeted therapy. The covalent modification of histones 
(such as methylation or acetylation) is an important 
mechanism of epigenetic regulation. Transcriptionally 
active gene promoters generally have hyperacetylated 
chromatin while transcriptionally silent genes have 
hypoacetylated chromatin. Histone acetyltransferases 
(HATs) catalyze the addition of acetyl groups onto histones 
and act as transcription co-activators. Conversely, Histone 
deacetylases (HDACs) are transcription co-repressors 
that remove acetyl groups from histones. There are three 
distinct classes of HDACs. Class I includes HDACs 1,2,3 
and 8, Class II HDACs 4-7 and 9-11, and Class III the 
SIR2 family. HDACs inhibit the expression of target 
genes to which they are bound by deacetylating Histone 
3 at lysines K9 and K14 in target promoters. HDAC 
inhibitors directly relieve repression of these targets by 
preventing Histone 3 K9 and K14 de-acetylation. H3 K9/
K14 deacetylation causes subsequent trimethylation of 
H3 on lysine 4 (H3K4me3) to maintain longer-term gene 
upregulation. 
Normal colon mucosa has high levels of Class I 
HDACs and CRCs have higher histone acetylation levels 
than normal colon [10, 11]. HDAC inhibitor treated APC 
mutant mice develop fewer intestinal adenomas [12]. 
Therefore, HDAC inhibition, and Class I HDAC inhibition 
in particular, is thought to be a promising strategy to 
improve anti-CRC chemotherapy. MGCD0103 is the first 
Class I selective HDACi to enter clinical trials. Phase I/
II clinical studies show that MGCD0103 is active against 
lymphomas [13-15]. Currently, non-class specific HDACi 
are FDA approved for treatment of lymphomas. Both class 
specific and pan-HDACi are also actively being evaluated 
in the treatment of a variety of solid tumors as well. 
WNT signalling plays a critical role in both CCIC 
and non-CCIC CRC cell proliferation and the majority 
of CRC tumors have increased WNT signaling [16, 17]. 
Canonical WNT signaling is initiated by ligand binding 
to Frizzled-Lrp5/6 cell surface receptors. This binding 
triggers a signaling cascade that causes β-catenin nuclear 
translocation. β-catenin binds to LEF/TCF transcription 
factors and upregulates genes important in proliferation 
and anti-apoptosis, such as MYC and CCD1. APC is a core 
component of the cytoplasmic “destruction complex” that 
degrades β-catenin via the proteasome. APC mutations 
are very common in CRC and cause constitutive WNT 
signaling by nuclear β-catenin. 
Dickopf (DKK) family proteins are extracellular WNT 
antagonists that bind to LRP5/6 with co-factors. DKK-1 is 
thought to be the most important family member in CRC. 
DKK-1 causes LRP 5/6 endocytosis and downregulation, 
inhibiting downstream canonical WNT signaling [18]. In 
transgenic mice, targeted overexpression of DKK-1 to the 
intestine inhibits proliferation of intestinal epithelial cells 
in villi and crypts [19]. DKK-1 also inhibits epithelial cell 
polarization and migration, processes that are important in 
tumor progression and metastasis [20]. 
DKK-1 expression is downregulated in human CRC. 
In many tumors DKK-1 is epigenetically silenced. In colon 
cancer cell lines where DKK-1 is epigenetically silenced, 
forced expression of DKK-1 inhibits proliferation and 
reduces xenograft tumor growth. Overall, DKK-1 is 
thought to act as a growth suppressor for CRC [21]. 
However, the mechanism of DKK-1 growth inhibition is 
poorly characterized.
We previously derived CCIC from primary CRCs 
[9]. To understand the mechanism of CCIC tumor 
formation we screened a variety of drugs for CCIC 
anti-proliferative activity. These included standard 
conventional cytotoxic chemotherapy drugs such as 
5-FU  and  oxaliplatin,  EGF  Receptor  inhibitors,  IGF1 
Receptor inhibitors, nitrosylated NSAIDs, and targeted 
agents including sunitinib and sorafenib, among others. 
CCIC were also resistant to almost all the agents screened, 
with the exception of the Class I HDACi MGCD0103. 
MGCD0103 effectively inhibits CCIC proliferation and 
clonogenicity. Furthermore, MGCD0103 is also active 
against commonly used non-CCIC CRC cell lines. These 
data were confirmed with the non-class specific HDACi 
Trichostatin (TSA). Gene expression profiling revealed 
that a mechanism of HDACi induced CCIC growth arrest 
and apoptosis is upregulation of the WNT antagonist 
Figure 1: Mccd0103 inhibits xenograft growth of 
multiple commonly used crc cell lines. NOD/SCID 
mice were injected in the lateral flank with one million cells of 
the indicated cell line and mice were treated with 40mg/kg 
MGCD0103 i.p. daily injections for three weeks. The decrease in 
xenograft tumor volume is indicated. Inhibition is the mean of two 
independent experiments for each cell line. 
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DKK-1. Overall, our data show that MGCD0103 is a 
promising approach to target CCIC as well as non-CCIC 
CRC cells. This dual activity is important because CCIC 
are highly chemoresistant. Our data also provide evidence 
that  DKK-1 can inhibit proliferation and clonogenicity 
even in CCIC that carry APC mutations. This result is 
consistent with a role for DKK1 to inhibit CCIC growth 
through mechanisms in addition to its role in canonical 
WNT signaling pathways and provides insight into the 
mechanisms of CCIC proliferation, tumor formation and 
chemoresistance. 
results
HdAc inhibitors have anti-ccIc and non-ccIc 
crc cell anti-proliferative activity 
To test if HDAC inhibitors have anti-tumor capacity 
in colon cancer we tested if Class I HDAC inhibitor 
MGCD0103 and TSA affected proliferation in colon 
cancer cell lines. We found that MGCD0103 had anti-
proliferative activity against colon cancer cell lines 
in  MTT  assays  with  an  IC50  value  of  0.7-1.0μM  in 
Figure 2: MGcd0103 impairs viability of ccIc. Cells were cultured in stem cell media in suspension and treated with MGCD0103 
and/or the combination of 5-FU/Oxaliplatin (FOLFOX). MTT assays were performed to assess cell viability after drug treatment. Error bars 
are S.E.M.
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commonly used CRC cell lines HCT15, HT-29, SW48 and 
SW620. For comparison the IC50 value for HMEC cells is 
19μM (table 1). In addition, cell cycle analysis of HCT15 
and HCT116 cells treated with MGCD0103 show G2/S 
phase cell cycle arrest and a sub-G1 accumulation (data 
not shown). Thus, Class I HDAC inhibitor MGCD0103 
inhibits proliferation of colon cancer cell lines and causes 
cell cycle arrest and apoptosis. 
To test if MGCD0103 had anti-CRC activity 
in xenograft models we treated mice injected with 
commonly used CRC cell lines including SW48, Colo 205 
and HCT116. When the tumors reached ~100mm3 mice 
were randomized into groups of 6-8 animals and treated 
with MGCD0103 i.p. or vehicle. Tumors were measured 
2-3 times a week for up to 3 weeks. Treatment of mice 
with MGCD0103 had anti-tumor activity in all commonly 
table 1: Mtt Ic50 Values (mM) of MGcd0103 in different 
Human cancer and normal cell lines
Table 1: MTT IC50 Values (µM) of MGCD0103 in Different Human Cancer and Normal 
Cell Lines
CELL LINE  IC 50
HCT15 0.7
HT-29 0.7
SW48 0.8
SW620 1.0
HMEC 19
(µM)
Figure 3: MGcd0103 inhibits ccIc d culture tumor formation. A. Representative pictures of xenograft tumors (left) and 3D 
culture glandular crypt-like tumors (right) from CCIC cell lines. b. Light microscopy view of 10cm plate of CCIC after MGCD0103 treatment 
in 3D matrigel culture at low magnification (left), 10X (middle) and 40X (right). 
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used CRC cell lines tested, as well as other solid tumor 
cell lines. For colon cancer the growth inhibition was 60% 
in an aggressive xenograft model such as HCT116 and 
almost complete growth inhibition in Colo205 (Figure 1). 
MGcd0103 inhibits ccIc viability
After demonstrating that MGCD0103 has anti-tumor 
activity in non-CCIC CRC cell lines, we next evaluated 
anti-CCIC activity, comparing MGCD0103 to standard 
conventional cytotoxic chemotherapy agents such as 
5-FU, and oxaliplatin and SN38/CPT-11. CCIC viability 
was  significantly  impaired  by  MGCD0103  (Figure 
2A). Consistent with previous results, CCIC are highly 
resistant to 5FU/oxaliplatin [7] (Figure 2b). Combining 
5FU/oxaliplatin and MGCD0103 further decreased CCIC 
viability and proliferation in a dose dependent manner 
(Figure 2b). To determine if this effect was specific to 
CCIC we treated CCIC and normal epithelial cell lines 
in the same experiment. When treated with MGCD0103, 
CCIC  viability  was  impaired  significantly  more  than 
MCF10A cells (Figure 2c). These data show that the 
same concentration of MGCD0103 reduces CCIC 
viability more effectively than the other cell types tested. 
Similar results were obtained when cells were treated with 
a pan-HDAC inhibitor TSA (data not shown). 
MGcd0103 inhibits ccIc clonogenicity and 
causes apoptosis in ccIc
Next we evaluated whether MGCD0103 inhibited 
the ability of CCIC to form tumour foci in vitro we used 
a 3D matrigel assay. In this assay CCIC are plated as 
single cells form tumor foci with organized glandular 
crypt like lumens and give rise to cells that express non-
CCIC CRC cell tumor markers [9] (Figure 3A). Using 
the 3D matrigel in vitro culture as previously described 
we treated CCIC with MGCD0103 for 72h and then 
cultured in normal media. We then quantified CCIC tumor 
formation in 3D culture in vitro. MGCD0103 treated cells 
formed no tumor foci. Only a few single, isolated CCIC 
cells were still observed (Figure 3B). Morphologically, 
cells have apoptotic bodies and lose self-renewal (Figure 
3B and data not shown). In summary, both MTS and 3D 
tumor formation assays are consistent with inhibition 
of proliferation as a mechanism of MGCD0103 action. 
Similar results were seen with TSA treatment (data not 
shown). Furthermore, cells treated with MGCD0103 and 
TSA were cultured in 3D cultures for up to 2 months after 
treatment to evaluate if cells can recover from a pulse of 
HDACi Even after two months of culture CCIC failed to 
recover and form tumor foci in 3D culture as compared 
to control. This suggests that HDAC inhibitors not only 
inhibit proliferation but can induce long-term (possibly 
permanent) changes in the CCIC epigenetic state that 
inhibit tumor formation.
To understand if HDACi treatment causes CCIC cell 
death we performed FACS and cell cycle analysis. This 
revealed that CCIC initiate apoptosis, indicated by the 
presence of a sub-G1 peak is present in CCIC treated with 
TSA (Figure 4A). In summary, HDACi causes CCIC cell 
cycle arrest, which is followed by cell death. 
HdAc inhibitors induce expression of dKK-1
The epigenetic state of CCIC is thought to be 
different from non-CCIC CRC cell lines. To identify 
the mechanism of HDACi induced growth arrest and 
apoptosis we performed gene expression profiling of two 
distinct CCIC lines treated with 0.7 µM MGCD0103, 
1 µM TSA or mock control for 6 hours. The short time 
period after treatment was used in order to focus on direct 
Figure 4:  HdAc inhibitors induce ccIc apoptosis. FACS cell cycle analysis plot of CCIC treated with vehicle only (mock), 200nM 
TSA or 800nM TSA for 24 hours. 
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targets of HDAC inhibition rather than downstream 
indirect transcriptional effects. We used Cyber T analysis 
to find differentially expressed genes between both groups 
i.e. control vs. MGCD0103 and control vs. TSA. The pan-
HDAC inhibitor TSA treatment caused differential gene 
expression (DEG) of 4440 target genes common to both 
CCIC lines, and the Class I HDAC inhibitor MGCD0103 
caused DEG of 2040 genes in the same lines. In many 
experiments, gene array studies can have a high false-
positive rate. To minimize the false positive rate, we 
focused our analysis on genes regulated up or down that 
were common to both the pan-HDAC and class I specific 
HDAC inhibitors and seen in both CCIC lines, which 
gave  a  set  of  1126  DEG.  The  significantly  regulated 
genes (PPDE = 0.99) in each group were then overlapped 
to find a common subset of genes that are differentially 
expressed in both treatment groups (Figure 5A). The gene 
list was used in NIH DAVID (Database for Annotation, 
Visualization and Integrated Discovery) (http://david.
abcc.ncifcrf. gov/) resource. DNA damage response and 
cell cycle arrest were among the top GO categories that are 
enriched (Table 2). Notably, the expression of the WNT 
antagonist  DKK-1 increased 18-fold in CCIC treated 
with TSA and 7.7-fold in MGCD0103 treated CCIC. To 
validate the array data we performed q-PCR analysis for 
DKK-1 on cells treated with increasing concentrations of 
TSA. TSA induces DKK-1 expression in a dose dependant 
manner, thus validating the array data (Figure 5B). 
Induction of DKK-1 by MGC0103 is not as robust as TSA 
under the time frame (6 hr) in qRT-PCR validation (data 
not shown). Overall, these analyses were consistent with 
a mechanistic role for DKK-1 in HDACi induced CCIC 
growth arrest and apoptosis. 
dKK-1 inhibits ccIc proliferation
To test if DKK-1 induced CCIC growth arrest and 
apoptosis we first transfected CCIC with an expression 
vector for DKK-1  or  GFP  control.  Equal  numbers  of 
CCIC were plated in 3D culture system to assay tumor 
foci formation. Cells transfected with DKK-1 had fewer 
and smaller tumor foci vs. GFP control (Figure 6A,B). 
Next, we used recombinant DKK-1 to treat CCIC already 
plated in 3D assays. Again, DKK-1 caused fewer and 
smaller tumor foci vs. control (Figure 6C). DKK-1 
inhibition of WNT signaling is upstream of APC and the 
beta-catenin destruction complex. As mutations in APC 
are common in CRC we tested if APC is mutated in 
CCIC. Western analysis revealed that the two CCIC lines 
studied both have APC protein truncations and no WT 
APC protein (Figure 6D). Next, we stained for β-catenin 
in xenograft samples from these CCIC lines. Nuclear 
β-catenin  is  an  indicator  of  active  WNT signaling. We 
Figure 5: Gene expression profiling reveals CCIC targets of MGCD0103 and TSA upregulation.  A. Venn diagram of 
differentially expressed genes (DEG) common for 2 CCIC cell lines treated with TSA or MGCD0103. b. Treatment with HDAC inhibitors 
upregulates expression of DKK-1 and DKK-3. Fold upregulation and p-value from quadruplicate data points for each of 2 CCIC lines from 
Affymetrix array data is shown. c. Q-PCR confirmation of DKK-1 upregulation by increasing concentrations of TSA. 
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table 2: top statistically enriched Gene ontology biological process categories for differentially expressed genes 
Table 2: Top statistically enriched Gene Ontology biological process 
categories for differentially expressed genes
Term Count % PValue Benjamini
GO:0007049 cell cycle 66 11.40% 5.84E-15 3.09E-11
GO:0022402c ell cycle processes 52 8.98% 7.76E-11 2.04E-07
GO:0006259~DNA metabolic process 54 9.33% 1.19E-09 2.08E-06
GO:0006334~nucleosome assembly 15 2.59% 4.37E-08 5.74E-05
GO:0000074~regulation of progression through cell cycle 36 6.22% 1.58E-07 1.66E-04
GO:0006950~response to stress 57 9.84% 1.72E-07 1.51E-04
GO:0051726~regulation of cell cycle 36 6.22% 1.80E-07 1.35E-04
GO:0031497~chromatin assembly 15 2.59% 2.53E-07 1.66E-04
GO:0065004~protein-DNA complex assembly 18 3.11% 3.35E-07 1.96E-04
GO:0006270~DNA replication initiation 9 1.55% 7.03E-07 3.69E-04
GO:0006260~DNA replication 22 3.80% 1.43E-06 6.84E-04
GO:0006333~chromatin assembly or disassembly 16 2.76% 3.75E-06 0.001639764
GO:0006974~response to DNA damage stimulus 24 4.15% 7.93E-06 0.00319912
GO:0022403~cell cycle phase 25 4.32% 1.19E-05 0.004469104
GO:0000279~M phase 22 3.80% 1.26E-05 0.004392701
GO:0006268~DNA unwinding during replication 6 1.04% 2.38E-05 0.007792704
GO:0009719~response to endogenous stimulus 26 4.49% 3.25E-05 0.009990679
GO:0032508~DNA duplex unwinding 6 1.04% 4.71E-05 0.013652474
GO:0032392~DNA geometric change 6 1.04% 4.71E-05 0.013652474
GO:0048523~negative regulation of cellular process 51 8.81% 6.61E-05 0.017204735
GO:0048519~negative regulation of biological process 52 8.98% 9.79E-05 0.024198433
GO:0006261~DNA-dependent DNA replication 12 2.07% 1.01E-04 0.023756591
GO:0006325~establishment and/or maintenance of chromatin architecture 21 3.63% 1.45E-04 0.0326071
GO:0006281~DNA repair 19 3.28% 1.48E-04 0.031823146
GO:0000075~cell cycle checkpoint 9 1.55% 1.53E-04 0.031601678
GO:0000278~mitotic cell cycle 21 3.63% 1.65E-04 0.032719024
GO:0006323~DNA packaging 21 3.63% 1.87E-04 0.03579105
GO:0065003~macromolecular complex assembly 30 5.18% 1.95E-04 0.035944691
GO:0007067~mitosis 17 2.94% 2.07E-04 0.036736724
GO:0000087~M phase of mitotic cell cycle 17 2.94% 2.28E-04 0.039230324Oncotarget 2010; 1:  596 - 605 603 www.impactjournals.com/oncotarget
found that nuclear beta-catenin is present in xenografts 
derived from both lines and is consistent with active 
WNT  signaling  (Figure  6E).  Similar  results  were  seen 
with 3Dculture CCIC tumors (data not shown). Overall, 
our data are consistent with DKK-1 as a potent inhibitor 
of CCIC proliferation and tumor formation, but through 
a mechanism that is independent of canonical WNT 
signaling. DISCUSSION:CRC metastatic recurrence and 
chemoresistance are major causes of cancer related death 
in the United States. Recent experiments have implicated 
a role for CCIC in both of these processes. Identifying 
novel compounds and drug combinations that target both 
CCIC and non-CCIC CRC cells is an important approach 
to improve CRC patient outcomes.
To identify potential anti-CCIC therapeutics 
we screened through a number of FDA approved and 
investigational drugs and found the class I HDACi 
MGCD0103 to be the most effective of the agents tested. 
We also found MGCD0103 to effectively inhibit the 
growth of non-CCIC CRC cells. Since Class I HDACs 
1-3 are over expressed in CRC [22] this latter finding is 
not completely unexpected. However, because CCIC are a 
minority of cells in tumors, the ability of Class I HDACi 
to inhibit these cells as well as non-CCIC bulk CRC cells 
is potentially important. Drugs inhibiting both CCIC and 
non-CCIC CRC cell tumor formation such as MGCD0103 
are anticipated to be particularly promising candidates to 
take forward in CRC developmental therapeutic clinical 
trials. 
MGCD0103 and TSA induce CCIC cell cycle arrest, 
and apoptosis. Mechanistically, our study provides insights 
into the primary targets of HDAC inhibition in CCIC. 
DKK-1 is epigenetically silenced in many CRCs but can be 
dramatically up-regulated by treatment with MGCD0103 
or TSA. Consistent with a functional role for DKK-1, both 
transfected and recombinant DKK-1 significantly reduce 
CCIC proliferation and clonogenicity in 3D cultures. 
Overall, our results suggest DKK-1 may be a useful 
pharmacogenetic biomarker for MGCD0103 clinical trials 
for CRC and possibly other solid tumors. Previous studies 
have shown that promoter hypermethylation causes DKK-
1 silencing in CRC and that this is not an early event but 
more closely associated with late tumor progression [21]. 
Because epigenetic state is thought to play an important 
role in the CCIC to non-CCIC CRC cell transition, it is 
tempting to speculate that HDACi upregulation of DKK-1 
transcription in CCIC may prevent subsequent promoter 
methylation in non-CCIC CRC daughter cells. Future 
immunohistochemistry co-localization studies in CRCs 
of DKK-1 and CCIC markers such as ALDH1 or CD44/
CD166 (and in parallel co-localization studies with non-
CCIC CRC cell markers such as CEA) will be useful to 
understand the precise role of DKK-1 expression in both 
CCIC and non-CCIC CRC cells.
Constitutive activation of canonical WNT signaling 
is a common feature of nearly all CRCs and DKK-
Figure 6: dKK1 inhibits ccIc tumor formation through non-canonical Wnt signaling pathways. Light microscopy of CCIC 
3D culture clonogenicity in cells transfected with DKK-1 expression vector (A) or addition of recombinant DKK-1 (c). b. Reduction in CCIC 
colony number with DKK-1 transfection. Error bars are S.E.M. d. Western blot showing loss of wild-type APC in CCIC-1 and CCIC-2 lines. 
Hela WT APC is shown as a positive control. e. Immunohistochemistry of CCIC xenograft tumors stained for beta-catenin. 
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1 has a clearly established role as a canonical WNT 
pathway inhibitor. Mutations in APC and less frequently 
β-CATENIN and AXIN are known to cause constitutive 
downstream signaling independent of upstream signals. 
However recent reports have suggested that upstream 
signaling from WNT inhibitors such as SFRP1, WIF-
1 and DKK-1 inhibit CRC cell growth even in presence 
of downstream mutations [21]. In contrast to sFRPs 
which decrease levels of β-CATENIN/LEF1 dependant 
transcription even in cells carrying APC mutations, DKK-
1 has minimal effect on these targets [21]. Because the 
CCIC lines we studied do not express WT APC, our study 
provides new evidence that DKK-1 inhibits proliferation 
through mechanisms that are independent of canonical 
WNT signaling. In mesothelioma cells DKK-1 activates 
the JNK pathway to induce apoptosis [23]. Since JNK 
signaling increases intestinal tumorgenesis in mouse 
models [24], future additional studies will be helpful to 
understand the role of JNK and other anti-proliferative 
mechanisms of DKK-1 in CCIC and non-CCIC CRC cells 
that are independent of canonical WNT signaling. 
MAterIAls And MetHods:
MGcd0103 and tsA treatment of ccIc
CCIC were plated in 3D culture (DAY 0) and treated 
with 0.7µM MGCD0103 (DAY 1) or 200nM TSA and 
treated for 48h. Controls were treated with DMSO or 
ethanol respectively. The cells were then cultured without 
drug for another 14 days or upto 2 months to assay number 
of colonies formed. 
ccIc transfection and dKK-1 treatment:
CCIC were transfected with DKK-1 expression 
vector (a kind gift from Dr. Marian Waterman) or GFP 
expression vector using Lipofectamine 2000 overnight. 
The cells were then trypsinzed counted and equal number 
of live cells were plated in each well for 3D assays. 
Recombinant DKK-1 was purchased from R&D systems. 
CCIC were plated in 3D wells and treated with recDKK-1 
at 10ng. CCIC were cultured for 14 days to assay affect on 
proliferation and colony formation. 
Protein Isolation and Western blotting
CCIC spheres were treated with TSA and cells 
were collected at different time points. The cell pellets 
were lysed in ice cold NP40 lysis buffer (50mM Tris-
HCl,  pH7.5,  150mM  NaCl,  1mM  EDTA  and  1%  NP-
40).  Protein  quantification  was  carried  out  using  Bio-
Rad Bradford protein quantification assay. Proteins were 
separated by SDS/PAGE and transferred to Immobilon-P 
PVDF (Millipore). Membranes were blocked with 5% 
nonfat dry milk and then incubated overnight at 4 °C with 
specific primary antibodies for Acetyl H3K9 and Acetyl 
H3K4 (Upstate Biotech) at dilutions recommended by the 
manufacturer. Detection was carried out by peroxidase 
based chemiluminesence and Dura West substrate (Pierce). 
Gene expression profiling
Two CCIC lines were treated with MGCD0103 
(0.71 µM) or TSA (200 nM) for 6h in quadruplicates and 
RNA was extracted using Qiagen RNeasy Spin columns. 
Expression  profiling  was  carried  out  using  total  RNA 
from CCIC lines on Affymetrix GeneChip Human Exon 
1.0 ST Array. RNA extraction, labeling, hybridization 
and scanning were carried out according to recommended 
protocols. The Cybet-T program was used to determine 
statistically  significant  differentially  expressed  genes 
compared to mock treated samples. Differentially 
regulated genes were analyzed by Ingenuity Pathway 
Analysis.
rnA isolation and quantitative rt-Pcr
Total RNA was extracted using Qiagen RNeasy 
Spin columns and reverse transcribed using ABI High 
capacity cDNA kit. Taqman Assay on demand was used to 
quantify gene expression on a ABI PRISM HT7900. Gene 
expression was normalized using GAPDH or RPLPO.
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